Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00765089 · ClinicalTrials.gov registry record · Phase 4
Bipolar Radiofrequency Ablation -Role in Prevention of Postoperative Atrial Fibrillation
A Phase 4 study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 4
- Development phase
- 35
- Enrollment target
NCT00765089 is a Phase 4 study that has completed, run by University of Pittsburgh. The registered enrollment target is 35 participants.
The verdict
NCT00765089, a Phase 4 study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 35 participants
- Enrollment target
Study Summary
Atrial Fibrillation (AF) is one of the most common postoperative complications after coronary artery bypass grafting (CABG). Postoperative AF produces a substantial impact on hospital resources with an estimated annual expenditure of over $1 billion. This includes the cost of pharmacological treatment and the cost of the increased length of stay. The incidence of AF is about 30-40% in CABG patients and increases with age of the patient. As the average age of the patient that undergoes CABG surgery is increasing, it is critical to find a way to prevent or reduce the incidence of this complication. We propose a prospective, randomized, controlled study to determine the role of pulmonary vein isolation by bipolar ablation in the prevention or reduction of postoperative AF. The block- randomization plan will be used to maintain balance of the study and control arms throughout the study.
Interventions
- PROCEDURE Isolation of pulmonary veins with Bipolar radiofrequency ablation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2005-12 |
| Est. Completion | 2010-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00765089
The ClinicalTrials.gov registry entry for NCT00765089 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Isolation of pulmonary veins with Bipolar radiofrequency ablation is the first listed.
NCT00765089 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00765089 about?
NCT00765089 is a clinical study titled "Bipolar Radiofrequency Ablation -Role in Prevention of Postoperative Atrial Fibrillation". Atrial Fibrillation (AF) is one of the most common postoperative complications after coronary artery bypass grafting (CABG). Postoperative AF produces a substantial impact on hospital resources with an estimated annual expenditure of over $1 billion. This includes the cost of pharmacological treatme...
What is the current status of trial NCT00765089?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 35 participants. The study started on 2005-12. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00765089?
The interventions under investigation include: Isolation of pulmonary veins with Bipolar radiofrequency ablation (PROCEDURE).
Who is sponsoring clinical trial NCT00765089?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.